HCA Healthcare Inc

HCA has formed a series of higher highs and higher lows since bottoming in mid-June and is holding above the rising 9-/20-day EMAs and 50-day SMA. Medium-term structure remains bullish within Stage 2, though the 200-day SMA overhead is a key hurdle. Short-term conditions favor participation now on shallow pullbacks into the EMAs, while a drop below the 50-day SMA would invalidate the current bullish bias.

• ↑Q2 2026 revenue of $20.23B (+8.7% YoY) with diluted EPS of $7.62
• ↑19th consecutive quarter of volume growth supports demand resilience
• ↓Insured-patient mix down 15%, reducing adjusted EBITDA by ~$400M